Approved & therapeutic
Dasiglucagon
Zegalogue
Dasiglucagon is a glucagon analog engineered to be stable in aqueous solution, approved in the US for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes who weigh at least 20 kg. It is supplied ready to use in a single-dose autoinjector or prefilled syringe, avoiding the reconstitution step of older lyophilized glucagon kits. IMPORTANT: it is no longer commercially available in the United States. The manufacturer announced discontinuation of all four presentations in February 2026, Drugs@FDA lists both products as Discontinued, and no generic exists. The FDA approval itself has not been withdrawn and the label was revised in June 2026, but patients should not expect to obtain this product and should discuss alternative rescue glucagon options with their clinician.
- Status
- Dasiglucagon is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Approximately 30 minutes.
- How it's taken
- Subcutaneous injection from a single-use autoinjector or prefilled syringe.
- Mechanism
- Metabolic (non-incretin)
- Pathways
- Glucagon
How Dasiglucagon works
Dasiglucagon is a glucagon receptor agonist with amino acid substitutions that confer stability in a ready-to-use liquid formulation. Receptor activation in the liver stimulates glycogen breakdown and the release of glucose into the circulation, raising blood glucose.
What research has looked at
- In the pivotal adult trial (Trial A, 170 patients), conducted using controlled intravenous insulin-induced hypoglycemia rather than spontaneous severe hypoglycemia, median time to plasma glucose recovery was 10 minutes with dasiglucagon versus 40 minutes with placebo (p<0.001). Recovery was defined as an increase in blood glucose of at least 20 points on the mg/dL scale without additional intervention within 45 minutes.
- In the second adult trial (Trial B, 45 patients), median time to recovery was 10 minutes versus 35 minutes with placebo (p<0.001).
- In the pediatric trial (Trial C, 42 patients aged 6 to 17, all weighing at least 20 kg), median time to recovery was 10 minutes versus 30 minutes with placebo (p<0.001).
- Against the reconstituted glucagon comparator arm, dasiglucagon was only numerically similar (10 versus 12 minutes in adults; 10 versus 10 minutes in children). The label states there was no formal hypothesis test versus glucagon for injection, so superiority over traditional glucagon kits has not been demonstrated.
- The product is a ready-to-use aqueous solution in a single-dose autoinjector or prefilled syringe, so no reconstitution step is required. This is a formulation characteristic; no trial measured bystander administration or real-world emergency outcomes.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Contraindicated in pheochromocytoma, because glucagon products may stimulate catecholamine release from the tumor and cause a substantial increase in blood pressure.
- Contraindicated in insulinoma, where administration may produce an initial rise in blood glucose but can stimulate exaggerated insulin release and cause subsequent hypoglycemia.
- Hypersensitivity and allergic reactions have been reported with glucagon products, including generalized rash and, in some cases, anaphylactic shock with breathing difficulties and hypotension.
- Lack of efficacy in patients with decreased hepatic glycogen. It is effective only if sufficient hepatic glycogen is present; patients in states of starvation, with adrenal insufficiency, or with chronic hypoglycemia may not respond and should be treated with glucose.
- Most common adverse reactions (at least 2 percent and more frequent than placebo) in adults were nausea (57 percent versus 4 percent placebo), vomiting (25 percent versus 2 percent), headache (11 percent), diarrhea (5 percent) and injection site pain (2 percent). In pediatric patients aged 6 to 17 they were nausea (65 percent), vomiting (50 percent), headache (10 percent) and injection site pain (5 percent).
- Drug interactions: patients taking beta-blockers may have a transient increase in pulse and blood pressure; in patients taking indomethacin, dasiglucagon may lose its ability to raise blood glucose or may produce hypoglycemia; it may increase the anticoagulant effect of warfarin.
- Overdose may cause nausea, vomiting, inhibition of gastrointestinal motility, increases in blood pressure and heart rate, and decreased serum potassium. There is no boxed warning on this label.
Sources
- PubMed research on Dasiglucagon · NIH · National Library of Medicine
- DrugBank record for Dasiglucagon · DrugBank
- Active clinical trials for Dasiglucagon · U.S. National Library of Medicine
Track Dasiglucagon in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Dasiglucagon FAQ
What is Dasiglucagon?
Dasiglucagon is a glucagon analog engineered to be stable in aqueous solution, approved in the US for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes who weigh at least 20 kg. It is supplied ready to use in a single-dose autoinjector or prefilled syringe, avoiding the reconstitution step of older lyophilized glucagon kits. IMPORTANT: it is no longer commercially available in the United States. The manufacturer announced discontinuation of all four presentations in February 2026, Drugs@FDA lists both products as Discontinued, and no generic exists. The FDA approval itself has not been withdrawn and the label was revised in June 2026, but patients should not expect to obtain this product and should discuss alternative rescue glucagon options with their clinician.
How does Dasiglucagon work?
Dasiglucagon is a glucagon receptor agonist with amino acid substitutions that confer stability in a ready-to-use liquid formulation. Receptor activation in the liver stimulates glycogen breakdown and the release of glucose into the circulation, raising blood glucose.
Is Dasiglucagon FDA approved?
Yes. Dasiglucagon is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Dasiglucagon?
Reported half-life: Approximately 30 minutes.
How is Dasiglucagon taken?
Subcutaneous injection from a single-use autoinjector or prefilled syringe.
What side effects have been reported with Dasiglucagon?
Reported in the sources: Contraindicated in pheochromocytoma, because glucagon products may stimulate catecholamine release from the tumor and cause a substantial increase in blood pressure; Contraindicated in insulinoma, where administration may produce an initial rise in blood glucose but can stimulate exaggerated insulin release and cause subsequent hypoglycemia; Hypersensitivity and allergic reactions have been reported with glucagon products, including generalized rash and, in some cases, anaphylactic shock with breathing difficulties and hypotension; Lack of efficacy in patients with decreased hepatic glycogen. It is effective only if sufficient hepatic glycogen is present; patients in states of starvation, with adrenal insufficiency, or with chronic hypoglycemia may not respond and should be treated with glucose; Most common adverse reactions (at least 2 percent and more frequent than placebo) in adults were nausea (57 percent versus 4 percent placebo), vomiting (25 percent versus 2 percent), headache (11 percent), diarrhea (5 percent) and injection site pain (2 percent). In pediatric patients aged 6 to 17 they were nausea (65 percent), vomiting (50 percent), headache (10 percent) and injection site pain (5 percent); Drug interactions: patients taking beta-blockers may have a transient increase in pulse and blood pressure; in patients taking indomethacin, dasiglucagon may lose its ability to raise blood glucose or may produce hypoglycemia; it may increase the anticoagulant effect of warfarin; Overdose may cause nausea, vomiting, inhibition of gastrointestinal motility, increases in blood pressure and heart rate, and decreased serum potassium. There is no boxed warning on this label.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.